Windlas Biotech IPO - Strong Outlook, Innovative Portfolio: KRChoksey
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
KRChoksey Research's IPO Report
Incorporated in 2001, Windlas Biotech Ltd. is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organisations segment in India.
The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It also sells its own branded products in the trade generics and over-the-counter markets.
Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders.
The business operates in three verticals namely CDMO products and services, domestic trade generics and over-the-counter markets and export markets.
Windlas Biotech owns and operates four manufacturing facilities located at Dehradun in Uttarakhand, with capabilities including formulation development, technology scale-up and full-scale commercial manufacturing, for both solid and liquid pharmaceutical dosage forms.
Click on the attachment to read the full IPO report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.